DK1654261T3 - Hepatitis C-inhibitorforbindelser - Google Patents
Hepatitis C-inhibitorforbindelserInfo
- Publication number
- DK1654261T3 DK1654261T3 DK04733750T DK04733750T DK1654261T3 DK 1654261 T3 DK1654261 T3 DK 1654261T3 DK 04733750 T DK04733750 T DK 04733750T DK 04733750 T DK04733750 T DK 04733750T DK 1654261 T3 DK1654261 T3 DK 1654261T3
- Authority
- DK
- Denmark
- Prior art keywords
- hepatitis
- inhibitor compounds
- compounds
- hcv
- protease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47270903P | 2003-05-21 | 2003-05-21 | |
PCT/CA2004/000750 WO2004103996A1 (en) | 2003-05-21 | 2004-05-19 | Hepatitis c inhibitor compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1654261T3 true DK1654261T3 (da) | 2008-01-14 |
Family
ID=33476973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04733750T DK1654261T3 (da) | 2003-05-21 | 2004-05-19 | Hepatitis C-inhibitorforbindelser |
Country Status (33)
Families Citing this family (165)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US7119072B2 (en) * | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
EA009295B1 (ru) | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
MY148123A (en) | 2003-09-05 | 2013-02-28 | Vertex Pharma | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
PE20050431A1 (es) * | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
AU2004282148A1 (en) * | 2003-10-10 | 2005-04-28 | Vertex Pharmaceuticals Incoporated | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US7132504B2 (en) * | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
DE602005025855D1 (de) * | 2004-01-21 | 2011-02-24 | Boehringer Ingelheim Pharma | Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus |
JP5248783B2 (ja) | 2004-01-30 | 2013-07-31 | メディヴィル・アクチエボラーグ | Hcvns−3セリンプロテアーゼインヒビター |
SI1718608T1 (sl) | 2004-02-20 | 2013-11-29 | Boehringer Ingelheim International Gmbh | Inhibitorji virusne polimeraze |
CA2556917C (en) | 2004-03-15 | 2013-07-09 | Boehringer Ingelheim International, Gmbh | Process for preparing macrocyclic compounds |
WO2005116054A1 (en) | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
JP4914348B2 (ja) * | 2004-06-28 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
UY29016A1 (es) * | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
MX2007003812A (es) * | 2004-10-01 | 2007-05-24 | Vertex Pharma | Inhibicion de proteasa ns3-ns4a del virus de la hepatitis c (vhc). |
TW201424733A (zh) | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
US7323447B2 (en) | 2005-02-08 | 2008-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2600367C (en) * | 2005-03-08 | 2014-08-12 | Boehringer Ingelheim International Gmbh | Process for preparing macrocyclic compounds |
CA2606195C (en) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Hcv ns3 protease inhibitors |
US7592336B2 (en) | 2005-05-10 | 2009-09-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN101242816B (zh) * | 2005-06-30 | 2012-10-31 | 维罗贝股份有限公司 | Hcv抑制剂 |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
US7601686B2 (en) | 2005-07-11 | 2009-10-13 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TWI389908B (zh) | 2005-07-14 | 2013-03-21 | Gilead Sciences Inc | 抗病毒化合物類 |
AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
MX2008001588A (es) | 2005-08-01 | 2008-02-19 | Merck & Co Inc | Inhibidores de proteasa ns3 del vhc. |
ES2401661T3 (es) * | 2005-08-02 | 2013-04-23 | Vertex Pharmaceuticals Incorporated | Inhibidores de serina proteasas |
US8076365B2 (en) | 2005-08-12 | 2011-12-13 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP1945605B1 (en) * | 2005-11-03 | 2013-01-09 | Boehringer Ingelheim International Gmbh | Process for preparing substituted anisidines |
US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2007130704A1 (en) * | 2006-01-25 | 2007-11-15 | Boehringer Ingelheim International Gmbh | A two step process for preparing substituted anisidines |
US7816348B2 (en) | 2006-02-03 | 2010-10-19 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
CA2643688A1 (en) | 2006-02-27 | 2007-08-30 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
KR20080112303A (ko) * | 2006-03-16 | 2008-12-24 | 버텍스 파마슈티칼스 인코포레이티드 | 중수소화 c형 간염 프로테아제 억제제 |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
WO2008008776A2 (en) | 2006-07-11 | 2008-01-17 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
MX2009000486A (es) | 2006-07-13 | 2009-01-27 | Achillion Pharmaceuticals Inc | Peptidos de 4-amino-4-oxobutanoilo como inhibidores de replicacion viral. |
US7718612B2 (en) * | 2007-08-02 | 2010-05-18 | Enanta Pharmaceuticals, Inc. | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
EP1886685A1 (en) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition |
RU2009109355A (ru) | 2006-08-17 | 2010-09-27 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Ингибиторы вырусной полимеразы |
US8309540B2 (en) | 2006-10-24 | 2012-11-13 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2008051475A2 (en) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8377873B2 (en) | 2006-10-24 | 2013-02-19 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
JP5268927B2 (ja) * | 2006-10-27 | 2013-08-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
CA2667032A1 (en) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Hcv ns3 protease inhibitors |
US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2008070358A2 (en) * | 2006-11-16 | 2008-06-12 | Phenomix Corporation | N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain |
AU2007335962B2 (en) | 2006-12-20 | 2012-09-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Antiviral indoles |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
JP2010519339A (ja) | 2007-02-26 | 2010-06-03 | アキリオン ファーマシューティカルズ,インコーポレーテッド | Hcv複製阻害剤として有用な三級アミン置換ペプチド |
WO2008106058A2 (en) * | 2007-02-27 | 2008-09-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
US8759353B2 (en) * | 2007-02-27 | 2014-06-24 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US8178491B2 (en) | 2007-06-29 | 2012-05-15 | Gilead Sciences, Inc. | Antiviral compounds |
EA200971074A1 (ru) | 2007-06-29 | 2010-08-30 | Джилид Сайэнс, Инк. | Антивирусные соединения |
JP2010533698A (ja) | 2007-07-17 | 2010-10-28 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | C型肝炎感染症の治療のための大環状インドール誘導体 |
AU2008277377B2 (en) | 2007-07-19 | 2013-08-01 | Msd Italia S.R.L. | Macrocyclic compounds as antiviral agents |
US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US8492546B2 (en) * | 2007-08-30 | 2013-07-23 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
JP2010540549A (ja) | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ,インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
US8962551B2 (en) * | 2007-12-05 | 2015-02-24 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl derivatives |
JP5529036B2 (ja) | 2007-12-05 | 2014-06-25 | エナンタ ファーマシューティカルズ インコーポレイテッド | フッ素化トリペプチドhcvセリンプロテアーゼ阻害剤 |
EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
TW201518507A (zh) | 2007-12-21 | 2015-05-16 | Celgene Avilomics Res Inc | Hcv蛋白酶抑制劑及其用途(二) |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8778877B2 (en) | 2007-12-21 | 2014-07-15 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8003659B2 (en) * | 2008-02-04 | 2011-08-23 | Indenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
JP5608563B2 (ja) * | 2008-02-25 | 2014-10-15 | メルク・シャープ・アンド・ドーム・コーポレーション | 治療用化合物 |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2271345B1 (en) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
US8044023B2 (en) | 2008-05-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
ES2491090T3 (es) | 2008-07-22 | 2014-09-05 | Merck Sharp & Dohme Corp. | Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC |
US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
AU2014201788B2 (en) * | 2008-09-16 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor |
JP5520301B2 (ja) * | 2008-09-16 | 2014-06-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 強力なhcv阻害剤である2−チアゾリル−4−キノリニル−オキシ誘導体の結晶形態 |
CN102159245B (zh) * | 2008-09-17 | 2013-07-24 | 贝林格尔.英格海姆国际有限公司 | Hcv ns3蛋白酶抑制剂与干扰素和利巴韦林的组合 |
EP2344487A4 (en) * | 2008-09-23 | 2012-03-21 | Boehringer Ingelheim Int | HEPATITIS C INHIBITOR COMPOUNDS |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
SG171771A1 (en) * | 2008-11-21 | 2011-07-28 | Boehringer Ingelheim Int | Pharmaceutical composition of a potent hcv inhibitor for oral administration |
ES2527166T3 (es) | 2008-12-10 | 2015-01-21 | Achillion Pharmaceuticals, Inc. | Nuevos péptidos de 4-amino-4-oxobutanoílo como inhibidores de la replicación viral |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
TW201034663A (en) | 2008-12-19 | 2010-10-01 | Gilead Sciences Inc | HCV NS3 protease inhibitors |
JP2012514605A (ja) | 2009-01-07 | 2012-06-28 | サイネクシス,インコーポレーテッド | Hcvおよびhiv感染の治療への使用におけるシクロスポリン誘導体 |
WO2010093843A2 (en) | 2009-02-12 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Hcv combination therapies |
WO2010107965A1 (en) | 2009-03-19 | 2010-09-23 | Boehringer Ingelheim International Gmbh | Process for preparing sulfonyl quinolines |
EP2411392B1 (en) * | 2009-03-26 | 2014-02-26 | Daewoong Pharmaceutical Co., Ltd. | Novel crystal forms of adefovir dipivoxil and processes for preparing the same |
TW201040181A (en) | 2009-04-08 | 2010-11-16 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
JP5647673B2 (ja) | 2009-05-05 | 2015-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ブロモ置換キノリンの調製方法 |
US8936781B2 (en) | 2009-05-13 | 2015-01-20 | Enanta Pharmaceuticals, Inc. | Macrocyclic compounds as hepatitis C virus inhibitors |
US8232246B2 (en) * | 2009-06-30 | 2012-07-31 | Abbott Laboratories | Anti-viral compounds |
CA2767692C (en) | 2009-07-07 | 2017-03-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition for a hepatitis c viral protease inhibitor |
US8828930B2 (en) | 2009-07-30 | 2014-09-09 | Merck Sharp & Dohme Corp. | Hepatitis C virus NS3 protease inhibitors |
WO2011017389A1 (en) | 2009-08-05 | 2011-02-10 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv |
US8324417B2 (en) | 2009-08-19 | 2012-12-04 | Virobay, Inc. | Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof |
WO2011049908A2 (en) * | 2009-10-19 | 2011-04-28 | Enanta Pharmaceuticals, Inc. | Bismacrokyclic compounds as hepatitis c virus inhibitors |
BR112012010110A2 (pt) | 2009-10-30 | 2019-09-24 | Boehringer Ingelheim Int | regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina |
US20130029904A1 (en) * | 2009-12-18 | 2013-01-31 | Boehringer Ingelheim International Gmbh | Hcv combination therapy |
TW201130502A (en) | 2010-01-29 | 2011-09-16 | Vertex Pharma | Therapies for treating hepatitis C virus infection |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
WO2012009503A1 (en) | 2010-07-14 | 2012-01-19 | Vertex Pharmaceuticals Incorporated | Palatable pharmaceutical composition comprising vx-950 |
NZ608720A (en) | 2010-09-21 | 2015-03-27 | Enanta Pharm Inc | Macrocyclic proline derived hcv serine protease inhibitors |
EA201300421A1 (ru) | 2010-09-30 | 2013-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Комбинированная терапия для лечения инфекции hcv |
US9011833B2 (en) * | 2010-10-08 | 2015-04-21 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
US10873191B2 (en) | 2010-11-19 | 2020-12-22 | Tseng-Lu Chien | Desk top alarm or time or LED lighting device has USB-port(s) |
US10873190B2 (en) | 2010-11-19 | 2020-12-22 | Tseng-Lu Chien | Desktop or floor LED lighting device has USB-port(s) |
CN103534256B (zh) | 2010-12-30 | 2016-08-10 | 益安药业 | 大环丙型肝炎丝氨酸蛋白酶抑制剂 |
JP2014506255A (ja) | 2010-12-30 | 2014-03-13 | エナンタ ファーマシューティカルズ インコーポレイテッド | フェナントリジン大環状c型肝炎セリンプロテアーゼ阻害剤 |
US9353100B2 (en) | 2011-02-10 | 2016-05-31 | Idenix Pharmaceuticals Llc | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8912141B2 (en) | 2011-06-23 | 2014-12-16 | Panmed Ltd. | Treatment of hepatitis C virus |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
UY34401A (es) | 2011-10-21 | 2013-05-31 | Abbvie Inc | Métodos para el tratamiento de hcv |
DE202012012956U1 (de) | 2011-10-21 | 2014-10-16 | Abbvie Inc. | Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen für die Verwendung zur Behandlung von HCV, umfassend Ribavirin aber nicht Interferon |
WO2013074386A2 (en) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
IN2014DN05759A (US08067438-20111129-C00013.png) | 2012-01-12 | 2015-04-10 | Boehringer Ingelheim Int | |
US20130195797A1 (en) | 2012-01-31 | 2013-08-01 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
WO2013137869A1 (en) | 2012-03-14 | 2013-09-19 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population |
WO2013147750A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
WO2013147749A1 (en) | 2012-03-27 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient subgenotype populations |
WO2013143581A1 (en) | 2012-03-28 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Combination therapy for treating hcv infection in specific patient subgenotype sub-population |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
JP5870001B2 (ja) | 2012-09-28 | 2016-02-24 | 株式会社吉野工業所 | ブロー成形装置及び容器の製造方法 |
ES2613766T3 (es) | 2012-10-19 | 2017-05-25 | Bristol-Myers Squibb Company | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914598B1 (en) | 2012-11-02 | 2017-10-18 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
JP6342922B2 (ja) | 2013-03-07 | 2018-06-13 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | C型肝炎ウイルス阻害剤 |
WO2014138374A1 (en) | 2013-03-08 | 2014-09-12 | Boehringer Ingelheim International Gmbh | Oral combination therapy for treating hcv infection in specific patient sub-population |
BR112015023343A2 (pt) | 2013-03-14 | 2017-07-18 | Achillion Pharmaceuticals Inc | método para preparar sovaprevir, método de preparar um composto da fórmula (c), método de preparação do composto f-2, composto, processo, método de preparação de uma forma amorfa pura de sovaprevir, e,forma cristalina de sovaprevir |
WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
EA032322B1 (ru) | 2013-03-15 | 2019-05-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Твердая пероральная дозированная композиция ингибитора hcv в аморфном состоянии |
US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
SG11201507467VA (en) | 2013-03-15 | 2015-10-29 | Achillion Pharmaceuticals Inc | Sovaprevir polymorphs and methods of manufacture thereof |
EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
AU2015274333A1 (en) | 2014-06-12 | 2017-01-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Heterocyclic compounds and methods of use thereof |
WO2017189978A1 (en) | 2016-04-28 | 2017-11-02 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
CN108610301B (zh) * | 2016-12-12 | 2021-08-31 | 中山大学 | 一类手性芳杂胺类衍生物及其合成方法和应用 |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US684806A (en) * | 1900-03-08 | 1901-10-22 | Filter & Brautechnische Maschinen Fabrik Akt Ges Vorm L A Enzinger | Pressure-regulator for pumps. |
AR205953A1 (es) * | 1975-01-22 | 1976-06-15 | Diamond Shamrock Corp | Produccion de carbonatos de metales a calinos en una celula de membrana |
EP0124317B1 (en) | 1983-04-27 | 1990-04-11 | Ici Americas Inc. | Proline derivatives |
JPH01103993A (ja) | 1987-10-16 | 1989-04-21 | Sumitomo Electric Ind Ltd | ダイヤモンド単結晶成長方法 |
JPH01135478A (ja) | 1987-11-19 | 1989-05-29 | Brother Ind Ltd | 研削工具 |
US5164402A (en) | 1989-08-16 | 1992-11-17 | Pfizer Inc | Azabicyclo quinolone and naphthyridinone carboxylic acids |
US5290405A (en) * | 1991-05-24 | 1994-03-01 | Ceramatec, Inc. | NaOH production from ceramic electrolytic cell |
JPH05155827A (ja) | 1991-12-09 | 1993-06-22 | Banyu Pharmaceut Co Ltd | cis−2−アミノシクロプロパンカルボン酸誘導体の製造法 |
HU221197B1 (en) | 1994-06-02 | 2002-08-28 | Aventis Pharma Inc | Elastase inhibitor tripeptides and pharmaceutical compositions comprising thereof |
DE4430601A1 (de) | 1994-08-22 | 1996-02-29 | Beiersdorf Ag | Zelladhäsions-Peptide zur Modifikation des Haftungsverhaltens eukaryontischer Zellen untereinander |
US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
DE4444893A1 (de) | 1994-12-16 | 1996-06-20 | Merck Patent Gmbh | Peptide und synthetische Zellmembranen |
GB9517022D0 (en) | 1995-08-19 | 1995-10-25 | Glaxo Group Ltd | Medicaments |
DE19600034C2 (de) | 1996-01-02 | 2003-12-24 | Degussa | 1,1,2-Trisubstituierte Cyclopropanverbindungen, Verfahren zu deren Herstellung und Dihydroxyethyl-substituierte 1-Amino-cyclopropan-1-carbonsäure |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
AU2933797A (en) | 1996-05-10 | 1997-12-05 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
CZ298749B6 (cs) | 1996-10-18 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
AU7127298A (en) | 1997-04-14 | 1998-11-11 | Emory University | Serine protease inhibitors |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
JPH10298151A (ja) | 1997-04-30 | 1998-11-10 | Japan Energy Corp | C型肝炎ウイルスプロテアーゼ阻害剤 |
JP2002512625A (ja) | 1997-05-29 | 2002-04-23 | メルク エンド カンパニー インコーポレーテッド | 細胞接着阻害薬としての複素環アミド化合物 |
JPH1135478A (ja) | 1997-07-17 | 1999-02-09 | Soyaku Gijutsu Kenkyusho:Kk | キク科植物の有機抽出物を含有する抗c型肝炎ウイルス剤及びプロテアーゼns3の特異的阻害剤 |
JP4452401B2 (ja) | 1997-08-11 | 2010-04-21 | ベーリンガー インゲルハイム (カナダ) リミテッド | C型肝炎ウイルス阻害ペプチドアナログ |
HUP0004853A3 (en) | 1997-08-11 | 2001-12-28 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptides, process for preparation thereof, pharmaceutical compositions comprising thereof, their use and their intermediates |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
JPH11127861A (ja) | 1997-10-29 | 1999-05-18 | Japan Energy Corp | C型肝炎ウイルス由来のセリンプロテアーゼに対する中和抗体部分ペプチド |
JP3612551B2 (ja) | 1997-11-07 | 2005-01-19 | 独立行政法人産業技術総合研究所 | C型肝炎ウイルスのns3プロテアーゼを阻害するrna分子 |
SE9704543D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Ab | New compounds |
IT1299134B1 (it) | 1998-02-02 | 2000-02-29 | Angeletti P Ist Richerche Bio | Procedimento per la produzione di peptidi con proprieta' inibitrici della proteasi ns3 del virus hcv, peptidi cosi' ottenibili e peptidi |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
EP1066247B1 (en) | 1998-03-31 | 2006-11-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
JPH11292840A (ja) | 1998-04-06 | 1999-10-26 | Soyaku Gijutsu Kenkyusho:Kk | ノルスタチン誘導体又はその塩 |
US6455571B1 (en) | 1998-04-23 | 2002-09-24 | Abbott Laboratories | Inhibitors of neuraminidases |
GB9809664D0 (en) | 1998-05-06 | 1998-07-01 | Hoffmann La Roche | a-Ketoamide derivatives |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
AR022061A1 (es) | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
AU1099000A (en) | 1998-10-05 | 2000-04-26 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions for treating hepatitis c infections |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
GB9825946D0 (en) | 1998-11-26 | 1999-01-20 | Angeletti P Ist Richerche Bio | Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
WO2001007407A1 (en) | 1999-07-26 | 2001-02-01 | Bristol-Myers Squibb Pharma Company | Lactam inhibitors of hepatitis c virus ns3 protease |
AU7511800A (en) | 1999-08-30 | 2001-03-26 | K.U. Leuven Research And Development | Novel target for antiparasitic agents and inhibitors thereof |
JP2001103993A (ja) | 1999-10-05 | 2001-04-17 | Japan Energy Corp | 環状ペプチド及びセリンプロテアーゼ阻害剤 |
US6222241B1 (en) * | 1999-10-29 | 2001-04-24 | Advanced Micro Devices, Inc. | Method and system for reducing ARC layer removal by providing a capping layer for the ARC layer |
GB9925955D0 (en) | 1999-11-02 | 1999-12-29 | Angeletti P Ist Richerche Bio | Hcv n33 protease inhibitors |
AU2055301A (en) | 1999-12-03 | 2001-06-12 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease |
WO2001058929A1 (en) | 2000-02-08 | 2001-08-16 | Schering Corporation | Azapeptides useful in the treatment of hepatitis c |
US6699855B2 (en) | 2000-02-29 | 2004-03-02 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
AU2001251165A1 (en) | 2000-04-03 | 2001-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
EP1268525B1 (en) | 2000-04-05 | 2008-12-31 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
CN1432022A (zh) | 2000-04-19 | 2003-07-23 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
US20020068702A1 (en) | 2000-07-21 | 2002-06-06 | Marguerita Lim-Wilby | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
DE60141608D1 (de) | 2000-07-21 | 2010-04-29 | Dendreon Corp | Peptide als inhibitoren der ns3-serinprotease des hepatitis c virus |
MXPA03000626A (es) | 2000-07-21 | 2004-07-30 | Schering Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c. |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
CN100391967C (zh) | 2000-11-20 | 2008-06-04 | 布里斯托尔-迈尔斯斯奎布公司 | 丙型肝炎三肽抑制剂 |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) * | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
CA2370396A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
CA2474156C (en) | 2002-02-01 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of ns3 (hepatitis c) |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
DE60324552D1 (en) | 2002-05-20 | 2008-12-18 | Bristol Myers Squibb Co | Substituierte cycloalkyl p1' hepatitis c virus inhibitoren |
AU2003299519A1 (en) | 2002-05-20 | 2004-05-04 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
PL211889B1 (pl) | 2002-05-20 | 2012-07-31 | Bristol Myers Squibb Co | Pochodna heterocyklosulfonamidowa, kompozycja ją zawierająca oraz ich zastosowanie |
US20040033959A1 (en) | 2002-07-19 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
WO2004101602A2 (en) | 2003-03-05 | 2004-11-25 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
JP4550824B2 (ja) * | 2003-03-05 | 2010-09-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎抑制化合物 |
EA009295B1 (ru) * | 2003-05-21 | 2007-12-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Соединения в качестве ингибиторов вируса гепатита с |
PE20050431A1 (es) | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
WO2005059205A2 (en) * | 2003-12-11 | 2005-06-30 | American Pacific Corporation | Electrolytic method to make alkali alcoholates using ceramic ion conducting solid membranes |
JP5248783B2 (ja) * | 2004-01-30 | 2013-07-31 | メディヴィル・アクチエボラーグ | Hcvns−3セリンプロテアーゼインヒビター |
WO2005116054A1 (en) | 2004-05-25 | 2005-12-08 | Boehringer Ingelheim International, Gmbh | Process for preparing acyclic hcv protease inhibitors |
RU2004119195A (ru) | 2004-06-24 | 2005-12-10 | Дмитрий Александрович Гертнер (RU) | Способ бесконтактной, гарантированной доставки товаров до конечного потребителя и система для его реализации |
JP4914348B2 (ja) | 2004-06-28 | 2012-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | C型肝炎インヒビターペプチド類似体 |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
ES2366478T3 (es) | 2004-07-20 | 2011-10-20 | Boehringer Ingelheim International Gmbh | Análogos peptídicos inhibidores de la hepatitis c. |
US20080245671A1 (en) * | 2007-04-03 | 2008-10-09 | Shekar Balagopal | Electrochemical Process to Recycle Aqueous Alkali Chemicals Using Ceramic Ion Conducting Solid Membranes |
US20090090638A1 (en) * | 2007-10-05 | 2009-04-09 | Kelly Michael T | Processes and reactors for alkali metal production |
US8246863B2 (en) * | 2009-06-26 | 2012-08-21 | Ceramatec, Inc. | Alkali metal super ionic conducting ceramic |
-
2004
- 2004-05-19 EA EA200501689A patent/EA009295B1/ru not_active IP Right Cessation
- 2004-05-19 PE PE2004000512A patent/PE20050204A1/es active IP Right Grant
- 2004-05-19 ES ES04733750T patent/ES2297424T3/es active Active
- 2004-05-19 PT PT04733750T patent/PT1654261E/pt unknown
- 2004-05-19 DE DE602004010137T patent/DE602004010137T2/de active Active
- 2004-05-19 NZ NZ544076A patent/NZ544076A/en not_active IP Right Cessation
- 2004-05-19 CN CN201310097223XA patent/CN103203010A/zh active Pending
- 2004-05-19 PL PL04733750T patent/PL1654261T3/pl unknown
- 2004-05-19 BR BRPI0410456A patent/BRPI0410456B8/pt not_active IP Right Cessation
- 2004-05-19 CN CNA2004800137831A patent/CN1791599A/zh active Pending
- 2004-05-19 JP JP2006529495A patent/JP4447603B2/ja not_active Expired - Fee Related
- 2004-05-19 UA UAA200512307A patent/UA83046C2/ru unknown
- 2004-05-19 RS YUP-2005/0871A patent/RS51294B/sr unknown
- 2004-05-19 MY MYPI20041902A patent/MY143076A/en unknown
- 2004-05-19 ME MEP-583/08A patent/MEP58308A/xx unknown
- 2004-05-19 EP EP04733750A patent/EP1654261B1/en active Active
- 2004-05-19 CN CN2013100935669A patent/CN103204903A/zh active Pending
- 2004-05-19 KR KR1020057022088A patent/KR101115294B1/ko active IP Right Grant
- 2004-05-19 AT AT04733750T patent/ATE378334T1/de active
- 2004-05-19 MX MXPA05012545A patent/MXPA05012545A/es active IP Right Grant
- 2004-05-19 AU AU2004240704A patent/AU2004240704B9/en not_active Ceased
- 2004-05-19 UY UY28323A patent/UY28323A1/es not_active Application Discontinuation
- 2004-05-19 CL CL200401161A patent/CL2004001161A1/es unknown
- 2004-05-19 CA CA2522577A patent/CA2522577C/en not_active Expired - Fee Related
- 2004-05-19 DK DK04733750T patent/DK1654261T3/da active
- 2004-05-19 WO PCT/CA2004/000750 patent/WO2004103996A1/en active IP Right Grant
- 2004-05-20 US US10/850,101 patent/US7585845B2/en active Active
- 2004-05-20 TW TW093114272A patent/TWI327145B/zh not_active IP Right Cessation
-
2005
- 2005-10-11 ZA ZA200508201A patent/ZA200508201B/en unknown
- 2005-11-17 IL IL172013A patent/IL172013A/en active IP Right Grant
- 2005-11-18 CO CO05117348A patent/CO5630024A2/es active IP Right Grant
- 2005-11-21 EC EC2005006181A patent/ECSP056181A/es unknown
- 2005-12-19 NO NO20056047A patent/NO332056B1/no not_active IP Right Cessation
-
2007
- 2007-06-21 US US11/766,171 patent/US7939667B2/en active Active
-
2008
- 2008-01-11 HR HR20080014T patent/HRP20080014T3/xx unknown
- 2008-02-14 CY CY20081100184T patent/CY1107200T1/el unknown
-
2009
- 2009-11-24 JP JP2009266291A patent/JP2010043129A/ja not_active Withdrawn
-
2011
- 2011-04-01 US US13/078,225 patent/US8067438B2/en active Active
- 2011-10-21 US US13/278,532 patent/US20120034187A1/en not_active Abandoned
-
2012
- 2012-07-03 US US13/540,859 patent/US20120269769A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1654261T3 (da) | Hepatitis C-inhibitorforbindelser | |
TW200615275A (en) | Hepatitis C inhibitor dipeptide analogs | |
EP1771454A4 (en) | PEPTIDE ANALOGUE AS HEPATITIS C HEMMER | |
TW200518746A (en) | Novel inhibitors of hepatitis C virus NS3/NS4A serine protease | |
DE602004029866D1 (de) | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c | |
ES2240446T3 (es) | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. | |
SG164376A1 (en) | Hcv ns3 protease inhibitors | |
RS20060197A (en) | Macrocyclic peptides active against the hepatitis c virus | |
EA201170241A1 (ru) | Макроциклические хиноксалиновые соединения в качестве ингибиторов протеазы вгс ns3 | |
CY1112108T1 (el) | Αναστολεις ιου ηπατιτιδας c | |
ATE497505T1 (de) | Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus | |
MX2009008872A (es) | Compuestos macrociclicos como inhibidores de proteasa ns3 del virus de hepatitis c. | |
UA90909C2 (en) | Hcv ns3 protease inhibitors | |
TH164044B (th) | สารประกอบยับยั้งตับอักเสบซี |